Fehniger JE, Berger AA, Juckett L, et al. - Researchers conducted comprehensive genomic sequencing in ovarian cancer samples collected during clinical care to recognize changes in mutational events over time. From 50 ovarian cancer patients in the Clearity Foundation Data Repository, they analyzed DNA from paired FFPE tumor samples for genomic mutations, copy number alterations, microsatellite status, tumor mutation burden, and loss of heterozygosity by hybrid-capture, next-generation sequencing of up to 315 genes. Outcomes revealed stable maintaining of the detected genomic alterations over time in most patients. Genes currently used for therapy selection indicated no discordant alterations. Discordant alterations were noted in genes used for clinical trial eligibility in 30%; repeat tumor testing detected 23% of these. Assays for tumor mutation burden and loss of heterozygosity revealed low discordance.